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Franco Scalambra,[a] Pablo Lorenzo-Luis,[b] Isaac de los Ríos[c] and Antonio Romerosa*[a] 
 
Abstract: This microreview summarizes some of the most 
significant findings published in the last years on metal complexes 
containing PTA and PTA derivatives ligands such as dmoPTA, with 
antiproliferative activity (PTA = 1,3,5-triaza-7-phosphaadamantane; 
dmoPTA = 3,7-dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane 
(dmoPTA). If significance, comments on other biological properties 
of the complexes are also indicated. 
1. Introduction 
The phosphane ligands 1,3,5-triaza-7-phosphaadamantane 
(PTA)[1] and its derivatives, such as the monometil derivative N-
methyl-1,3,5-triaza-7-phosphaadamantane (mPTA) and the 3,7-
dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane (dmoPTA), 
are versatile ligands able to coordinate mainly to metals by both 
its phosphorous and nitrogen atoms (Figure1). The metal 
complexes containing these phosphanes usually display 
interesting properties various fields such as catalysis,[2] materials 
design,[3] and particularly they display significant antiproliferative 
activity towards different cancer cell lines, including platinum 
resistant cancer cells. [4–6] 
Coordination compounds with metals other than platinum, 
particularly ruthenium(II)-based complexes, are emerging as 
promising antiproliferative and antimetastatic agents with 
potential uses. Since FDA approval in 1978, cisplatin,[7–10] has 
been used in medical cancer treatment, which is notable as it 
was the first transition metal complex found to have anticancer 
activity. It is also worth to stress that cisplatin is effective against 
cancers such as sarcomas, carcinomas (small cell lung and 
ovarian cancer), lymphomas, and germ cell tumours. 
Nevertheless, this platinum complex displays two important 
issues: the emergence of resistance and toxicity to normal 
tissues.[11–16] Additionally, cisplatin shows other problems such 
as: its administration has to be intravenous, its negative side 
effects and its high price due the low abundance of Pt. These 
problems have pushed the worldwide researchers to find new 
active anticancer metal complexes based on cheaper and less 
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Figure 1. Structures of PTA and derivatives named in this paper. 
 







The fact that not all of the Pt complexes displayed 
anticancer activity suggested from the beginning that the 
selection of adequate ligands is very important to obtain an 
anticancer active metal complex. Ligands could stabilize a 
particular metal coordination geometry and oxidation state, and 
are also very important to determine the complex solubility. 
Particularly, the hydrophilic/hydrophobic balance is central for 
the in vivo behaviour and efficiency of a metal complex under 
physiological conditions: it should be soluble enough in water, 
which is the main component of physiological fluids, but also in 
organic media to pass through the cellular membrane into the 
cell.[4–6,17] The ligands PTA and dmoPTA have showed to be 
excellent to stabilize low valence metal oxidation states and 
provide an adequate hydrophilic/hydrophobic balance. These 
ligands are usually stable, easy to be prepared and soluble in 
water and organic solvents.  
There are recent reviews that present comprehensively 
complexes with PTA and some PTA derivatives.[18-20] Due to 
their novelty monometallic and heterometallic complexes 
containing the ligand dmoPTA have not been reviewed until now. 
This minireview wants to fill this gap by summarizing the 
published complexes containing dmoPTA and, for the sake of 
comparison, the most significant metal complexes displaying 
antiproliferative activity containing PTA and its derivatives. 
2. Complexes with PTA and Derivatives 
different to dmoPTA 
 
In 2011 Dyson et al. showed that is possible to prepare a 
family of organometallic ruthenium complexes containing PTA 
with substantial anticancer activity, particularly effective against 
platinum resistant cancer cells.[4] These complexes, generically 
named RAPTA (Figure 2), have been exstensively studied, 
inducing the broad use of the ligand PTA and its derivatives as 
constituent of antiproliferative and antimicrobial active metal 
complexes. Nice and recent reviews have been targeted to 
describe the antiproliferative properties of the complexes 
containing PTA and its derivatives,[18–20] some of them being 
mainly focused on RAPTA complexes.[4,21–25]  
There are valuable and very interesting examples of very 
active antiproliferative transition metal complexes containing 
ligands of the PTA family, being platinum and ruthenium among 
the most represented metals.[26] Lately new Ru complexes with 
significant antiproliferative activity including also PTA derivatives, 
but different to the RAPTA family, have been published. It is 
worth mention the Pt(II) and Ru(II) complexes cis-[PtCl2(L)2]X2 
(4-6) and [RuCpCl(PPh3)(L)]X (7-9) (L = 1, 2, 3, X = Br, Cl, PF6), 
which contain the PTA derivatives (PTAC2H4OCOMe)X (1) (X = 
Br- (1Br), PF6- (1PF6)), (PTACH2COOEt)X (2) (X = Br; (2Br) X = 
Cl (2Cl), X = PF6 (2PF6)) and (PTACH2CH2COOEt)X (3) (X = 
PF6, 3PF6). These complexes show comparable antiproliferative 
activity to cisplatin and salts 1PF6, 2Cl, and 3PF6 were also 
found to interfere with the cholinergic cascade involved in 
Alzheimer disease. These complexes could also act as carriers 
for metal ions through the blood−brain barrier, allowing them to 
act as metallotherapeutics in the central nervous system.[27]  
Other attractive complexes are the neutral [Ru(N–N)(PTA)2Cl2] 
(N–N = bpy (10), N–N = phen (11)), monocationic [Ru(N–
N)(PTA)3Cl]Cl (N–N = bpy (12), N–N = phen(13)) and, dicationic 
[Ru(N–N)(mPTA)Cl2](BF4)2 (N–N = bpy (14), N–N = phen (15)) 
(bpy = 2,2’-bipyridyl; phen = 1,10-phenanthroline; mPTA = N-
methyl-1,3,5-triaza-7-phosphaadamantane) (Scheme 1). 
Complex 11 was found to be the most effective in blocking cell 
cycle, inducing also necrotic cell death in Multiple Myeloma 
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Figure 2. Structure of RAPTA-T and RAPTA-C. 






(MM) cell lines.[28] Homeostasis of organisms depends on an 
intricate balance between cell death and renewal, which could 
be disrupted by diseases and external agents.  
Recently new Pt-PTA complexes (16, 17, Scheme 2) with 
improved antiproliferative properties have been published.[29–31] It 
was showed that the co-ligands bonded to the {Pt(2,2-bpy)} + 
moiety have a large influence on the reaction kinetics of the 
complexes with biomolecules such as amino acids, proteins, and 
DNA.[30] The ligand PTA decreases the reactivity of the its metal 
complexes with biomolecules but increases antineoplastic 
activity. The final conclusion is that it is possible to fine-tune 
Pt(II) compounds, targeting different cancer pathways 
overcoming the side effects associated with cisplatin. In contrast, 
PTA containing Pt(II) complexes [PtCl(hq)(pta)] (18-25) (hq = 5-
chloro-7-iodo-8-quinolinol (18), 8-hydroxy-5-nitroquinoline (19), 
5,7-dichloro-8-quinolinol (20), 5,7-diiodo-8-quinolinol (21), 5,7-
dibromo-8-quinolinol (22), 5,7-dichloro-8-hydroxy-2-methyl-
quinoline (23), 8-hydroxyquinoline (24) and 8-quinolinethiol (25)) 
(Scheme 3) showed good selectivity towards cancer cells with a 
possible mode-of-action involving the increase of reactive 
oxygen species (ROS) generation and good embryo toxic profile. 
Complex [PtCl(5,7-dibromo-8-hydroxyquinolinato)(PTA)] (22) 
was showed to be the most promising complex for 
therapeutically applications.[31]  
Even if Ru and Pt complexes are the most popular among the 
antiproliferative metal compounds, the Re-PTA, Re-DAPTA and 
RE-THP complexes [Re(CO)3(NN)(L)]+ (26-35) (NN = diimine 
ligand; DAPTA = 1,4-diacetyl-1,3,7-triaza-5-
phosphabicylco[3.3.1]nonane; THP = 
tris(hydroxymethyl)phosphine) have been showed to be highly 
cytotoxic (Scheme 4). It is important to point out that THP-Re 
and DAPTA-Re compounds display triplet-based luminescence 
in air-equilibrated aqueous solutions (Φ = from 3.4 to 11.5%), 
photo substitute one CO ligand (365 nm light; Φ = from 1.1 to 
5.5%) and sensitize the formation of 1O2 (Φ = up 70 %). In 
contrast and interestingly, complexes with PTA are non-emissive 
and do not undergo photo substitution. Assessment under light 
of the activity of the complexes against human cervical HeLa, 
ovarian A2780, cisplatin-resistant ovarian A2780 and CP70 
cancer cell lines, showed that THP and DAPTA complexes 
exhibit a cytotoxic response upon irradiation with minimal toxicity 
in the absence of light. The complex with DAPTA and 1,10-
phenanthroline displayed an IC50 value of 6 μM in HeLa cells, 
which was the highest until that moment.[32]  
Other interesting antimetastatic compounds are the 
[Rh(Cp*)Cl(X,Y)]n+ (X, Y = Cl, PTA, n = 0 (36); X, Y = en, n = 1; 
X, Y = acac, n = 0; X, Y = cur, n = 0, where Cp* = 
Scheme 1. Structure of Pt and Ru complexes of PTA 7-9. 
Adapted from ref [27]. 
Scheme 2. Synthesis and structure of complexes 10-15. Adapted 
from ref [28] 
Scheme 3. Structures of complexes 16-25. Adapted from ref [31] 






pentamethylcyclopentadienyl; cur = curcumin; en = 1,2-
ethanediamine; acac = 2,4-pentanedionato).[33] These 
complexes are not more active than cisplatin but they suffered 
easily ligand-exchange substitution reactions with biomolecules. 
Unfortunately, complex 36, which is the only one containing PTA, 
is not cytotoxic. 
It is important to point out that PTA-Cu(I) and PTA-Ag(I) 
complexes [M(PTA)4]+ (M = Cu+ (37), Ag+ (38), Au (39)) 
(Scheme 5) display potential clinical use as antiproliferative 
agents. The combination of DFT calculations and 
thermodynamic experimental data was used to estimate the 
stability constants of the complexes supporting that ligand PTA 
prefers Cu(I) to the Ag(I). Complexes 37 and 38 dissociate into 
stoichiometrically-lower species when diluted to the micromolar 
concentration range, such as it is typical in vitro testing. 
Complexes [Cu(PTA)2]+, [Cu(PTA)3]+ and [Ag(PTA)2]+ are 
predicted to be the species involved in the cytotoxic mechanism 
of these compounds.[34]  Complexes 37, 39 display a high 
antiproliferative activity for a wide range of solid tumours, also 
platinum-drug resistant.[35]  Complex  39 is neurotoxic, and 
produces the inhibition of proteasome activity in DRG neurons 
even at lower concentrations than the IC50, while copper 
complex 37 does not induce neurotoxicity. Experiments In vitro 
and in vivo showed that copper complex 37 is more active as 
antiproliferative agent and also show reduced peripheral 
neurotoxicity profile. Preliminary results obtained from studies 
made in vivo with mice showed that copper compounds are 
markedly better tolerated with respect to the reference platinum 
drugs.[36] Furthermore, the complex [Cu(THP)4]PF6 displays 
efficacy in the treatment of Lewis pulmonary tumour in mice in 
both early and advanced stage treatment schedule.[37]  
New PTA-thiolate-gold(I) complexes 40-53 have showed 
optimal hydro/lipophilicity properties (Scheme 6).[38] Their activity 
against Caco-2 cells was found to be very high and similar to 
that found for auranofin. Interesting, these complexes displayed 
a very low cytotoxic against enterocyte-like differentiated cells. 
The stability under physiological conditions was permitted by the 
thiolate ligands, which confer to the complexes also a larger 
cytotoxic activity. It is also interesting to point out that the 
presence of a substituent as −NO2, which is a typical electron-
withdrawer, in the benzene-para position of these PTA 
derivatives led to a better stability and lipophilicity but does not 
improve significantly the antiproliferative activity. The 
mechanistic studies showed that these complexes induce cell 
death by arrest of the cell cycle and apoptosis, facilitating the 
reduction of 5-fluorouracil dose, but also by increasing the 
intracellular ROS levels. The reason for this last finding was 
proposed to be the interaction of the complexes with the enzyme 
TrxR, which produce the modification of the cell the redox 
balance.  
Very attractive antiproliferative water soluble silver complexes 
were obtained with the PTA derivative 3,7-dimethyl-1,3,5-triaza-
7-phosphabicyclo[3.3.1]nonane (PTN) (54(a-f)-55(a-f)) (Scheme 
7).[39] The ligand PTN was found to be P,N bidentate when only 
two ligands are coordinated to the metal, while only P-mono-
coordination to the metal center was observed for complexes 
with three ligands. The silver complexes, in which the ligand is 
bis-coordinated, decompose under air but also under visible light 
irradiation also in inert atmosphere. Nevertheless, parent tris-
ligated complexes display greater stability both under air and 
particularly to photodecomposition. Single crystal X-ray structure 
of 54 and 55 showed that, as expected, there is a strong bond 
between silver and the phosphorus atom but a very weak bond 
with the terminal nitrogen atom, particularly in the bis-ligated 
complexes 54b and 54e. The crystal structure of 55d is 
Scheme 4. Structure and synthesis of complexes 26-35. Adapted from ref 
[32]. 
Scheme 5. Structure of complexes 37, 38 and 39. Adapted from ref [34] 
Scheme 6. Structure of complexes 40-53. Adapted from ref [38] 






constituted by a silver bonded by a pseudo κ2-P,N binding mode. 
Density functional theory (DFT) studies revealed that the bi-
substituted PTN-Ag(I) species are characterized by a total 
enthalpy for the tetrahedral C2-symmetric structure, marginally 
lower by −0.6 kcal mol−1 than that for the planar C2h structure. 
This results were analogous to that found for the parente 
{Au(PTN)2}+ complex (ΔH = −0.5 kcal mol−1).  
The antimicrobial and antifungal activity of these complexes 
were evaluated using the agar well diffusion test. The activity 
was found to be correlated with the counterion nature, being 
silver complexes with the deprotonated triclosan as the 
counterion the most active. Complexes containing triclosan 
showed the best activity but complexes 54f and 55f showed to 
have similar or higher activity than triclosan, depending on the 
microorganism tested. The study shows how the metal nature is 
important for obtaining an adequate antibacterial activity but also 
the presence of the triclosan anion is an important factor for 
obtaining a high anti-microbial activity. 
In addition to the monometallic complexes containing PTA, 
also polymetallic complexes with antiproliferative and 
antimicrobial activity were described,[40–42] but they were 
included and discussed in the previously indicated reviews. 
Nevertheless, it is worth to mention that studies targeted to 
evaluate their stability in physiological conditions have not been 
performed yet and therefore there is scarce knowledge on the 
real antiproliferative active species. 
 
3. Complexes with dmoPTA 
2.2. Heterometallic Complexes 
As indicated in the introduction, researchers are looking for new 
PTA derivatives with similar but specifically tuned 
properties.[18,20,43] A huge number of new ligands derived from 
PTA have been synthesized and some representative metal 
complexes obtained. Nevertheless, there are few examples of 
bi-functionalization of the PTA at the two N,. In particular, mono-
methylation of PTA on one N is a trivial reaction but multi-
methylation, usually yields a mixture of compounds.[12–15,44] 
Finally, the bi-N-methylated PTA, N,N’-dimethyl-1,3,5-triaza-7-
phosphaadamantane (dmPTA), and its derivative 3,7-H-3,7-
dimethyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane 
(HdmoPTA) weres obtained by reaction of PTA with 2 equiv of 
Me(CF3SO3) in refluxing acetone (Scheme 8).[45,46] The ligand 
dmPTA is soluble in water and organic solvents such as CDCl3, 
acetone, etc., and it is stable enough in non protic solvents. 
Nevertheless, in presence of protic solvents such as EtOH, 
MeOH or H2O, the ligand dmPTA suffers the elimination of the 
CH2 group between the NCH3 atoms giving rise to the new 
HdmoPTA, which can be isolated as tetrafluoroborate salt by 
reaction with HBF4. This ligand can be easily deprotonated and 
the resulting neutral phosphane-amine 3,7-dimethyl-1,3,7-triaza-
5-phosphabicyclo[3.3.1]nonane (dmoPTA) is able to coordinate 
metals by the soft P but also through the two hard NCH3 atoms, 
behaving in the latter case as a chelate (Scheme 8).[44] The 
ligand dmoPTA is somewhat soluble in water but displays good 
solubility in organic solvents such as CHCl3, acetone, toluene, 
etc.  
The reaction of dmPTA(CF3SO3)2 with [RuClCp(PPh3)2] in 
refluxing acetone/MeOH/water, gives the yellow complex 
[RuClCp(1κP-HdmoPTA)(PPh3)](OSO2CF3) (56), which was the 
first component of the the so-called 1st generation of complexes 
containing the ligand dmoPTA (Scheme 9).[46]  
The proton between both NCH3 atoms in 56 can be 
removed easily using a 0.01 M KOH water solution or tBuOK in 
MeOH at room temperature, which gives the option to the ligand 
to coordinate a second metal through the NCH3 atoms. In fact, 
The distance between the methylated nitrogens (2.702(12) Å) is 
adequate to chelate a metal without inferring significant 
distortion to the dmoPTA cage. Therefore the ligand could be 
coordinated through the P and NCH3 atoms. The reaction of 56 
with tBuOK and M(acac)2 in methanol leads to the bimetallic 
complex [RuClCp(PPh3)-μ-dmoPTA-1κP:2κ2N,N’-M(acac-
κ2O,O´)2] (M = Co (57), Ni (58), Zn (59)) in which the dmoPTA is 
bonded to the Ru by the P and by the NCH3 to the metal M 
(Figure 3, Scheme 9).[47,48]  
Scheme 7. Synthesis and structure of 54 and 55. Adapted from ref [39]. 
Scheme 8. a) Synthesis of dmPTA; b) Formation of dmoPTA from 
dmPTA; c) acid/base equilibrium dmoPTA/HdmoPTA. 






Interestingly, complex Ru-redox properties depend on the 
metal bonded to the atoms NCH3, which could be a consequence 
of steric but mainly due to electronic effects. Therefore, the unit 
{dmoPTA-κ2N,N’-M}m+ can be considered as a new ligand 
derived from PTA, whose properties can be tuned by the 
appropriate selection of the metal, its oxidation state and its 
ancillary ligands.  
Monomeric Ru complex 56 and bimetallic Ru-M complexes 
57-58 inhibit cell proliferation of human solid tumour cell lines 
with a better activity profile (Table1) than the standard 
anticancer drugs cisplatin, NAMI-A, KP1019 and RAPTA 
complexes (Scheme 1). Additionally, cell cycle analysis points 
out that the new Ru(II) complexes act by a different action 
mechanism than cisplatin as cell cycle arrest in G1 and there is 
an absence of interaction with DNA (Figure 4).[16] Nevertheless, 
the exact biological target has not been identified yet. 
To have more information on how the metal bonded to the 
dmoPTA-NCH3 atoms modulate the chemical properties of the 
{RuCpCl(dmoPTA)(PPh3)}-moiety, the new bimetallic complexes 
Scheme 9. Synthesis of 56-62. 
Figure 3. Representation of the crystal structures of complexes 55-61. Adapted from ref [45-49]. 
Figure 4. Cell cycle phase distribution of untreated cells (C) and cells 
treated with Ru(II) complexes 55–58 and cisplatin (CDDP) for 24 h. 
Adapted from ref [16]  






[RuClCp(PPh3)-μ-dmoPTA-1κP:2κ2N,N′-MCl2] (M = Co (60), Ni 
(61) and Zn (62)) were synthesized (Scheme 9), which contain 
the simple and more reactive {MCl2} unit, by a procedure similar  
to that used for synthesizing the bimetallic complexes 57-
59.[49] These complexes showed similar properties than those 
with acac,[45] particularly the ruthenium atom of the 
{RuCpCl(dmoPTA)(PPh3)}-moiety was found to have a clear 
sensitiveness to the metal bonded to NCH3 but also to the ligands 
bonded to this metal. Therefore the unit {dmoPTA-κ2N,N’-MX2} 
can be considered such as a family of ligands with properties 
related but different than those for dmoPTA. This finding open 
the door to obtain new ligands with very precise tuned properties 
by a clever selection of metals (M) and its ancillary ligands (X). 
The antiproliferative activities of compounds 60-62 were 
studied in the panel of human solid tumour cells HBL-100, HeLa, 
SW1573, and WiDr (Table 1). Compounds containing {CoCl2} 
(59) and {NiCl2} (60) units showed somewhat more potent 
activity than the Ru-ZnCl2 (61). Nevertheless, all complexes 
induce growth inhibition in all cell lines with GI50 values in the 
range 0.8–6.5 μM, which are clearly better than those for 
cisplatin. It is important to stress that the activity is particularly 
high against the breast T-47D and the colon WiDr cells that are 
less sensitive to cisplatin. The results point out that the three 
compounds are active in both drug-sensitive (HBL-100) and 
drug-resistant (T-47D and WiDr) cell lines.  
It was determined that Ru-CoCl2 (60) and Ru-NiCl2 (61) 
complexes are transformed quickly in a DMSO–water mixture 
into [RuClCp(dmoPTA)(PPh3)]+ by releasing  the {MCl2} unit. 
These experimental facts suggested that antiproliferative 
activities of 60 and 61 are probably due to the released 
[RuClCp(dmoPTA)(PPh3)]+ cationic complex. In contrast, the 
complex Ru-ZnCl2 (62) was found to be stable enough over the  
antiproliferative experiment time, being the amount released of 
the cationic complex [RuClCp(dmoPTA)(PPh3)]+ non-significant. 
These results suggest that the observed activity should be 
associated exclusively to the action of the bi-metallic complex. 
This suspicion was confirmed by the fact that the antiproliferative 
activity of 63 is similar but somewhat larger than those for 
starting complex [RuClCp(HdmoPTA)(PPh3)](OSO2CF3) and 
former bimetallic complexes containing acac (57-59), which are 
stable enough in a DMSO–water mixture.  
To elucidate whether the exchange of the chlorine bonded 
to the ruthenium is implicated in the antiproliferative activity of 
this family of complexes and therefore has some importance in 
the action mechanism as observed for platinum complexes, this 
ligand was substituted. The phosphane PPh3 was selected as 
substituted of the Cl as it is a stable ligand that usually is 
strongly bonded to the Ru and could provide extra lipophilic 
solubility to the final complex, as well as it can be easily studied 
by 31P NMR.  
Abstraction of the chloride in 
[RuClCp(HdmoPTA)(PPh3)](OSO2CF3) by AgCF3SO3 and further 
reaction with one mole of PPh3 leads to the complex 
[RuCp(PPh3)2(HdmoPTA-1κP)](CF3SO3)2 (63), which as 
        


















56   1.9 (±0.5) 1.5 (±0.1) 2.6 (±0.2) 1.7 (±0.4) 710(5) -2.93 CD3OD 
57   1.9 (±0.1) 1.4 (±0.2) 2.3 (±0.6) 1.5 (±0.4) 915(5) 51.56 CD3OD 
58   2.0 (±0.3) 1.4 (±0.1) 2.5 (±0.1) 1.6 (±0.2) 812(5) 62.6 CDCl3 
59   2.3 (±0.6) 1.4 (±0.4) 2.6 (±0.3) 2.6 (±0.3) 900(5) -0.93 CDCl3 
60   1.4 (±0.2) 1.1 (±0.1) 1.3 (±0.1) 1.5 (±0.3) 840(5) 277 CDCl3 
61   1.2 (±0.2) 1.0 (±0.1) 1.4 (±1.1) 1.1 (±0.2) 770(5) 152 CDCl3 
62   6.5 (±3.0) 4.6 (±0.1) 4.0 (±0.1) 5.7 (±1.4) 798(5) 2.56 CDCl3 
















     211.35 CDCl3 






 –15.10 CDCl3 
cisplatin   1.5 (±2.3) 3.0 (±0.4) 2.0 (±0.3) 2.6 (±5.3)    
  Table 1. GI50 of complexes 56-66 compared to cisplatin.  Adapted from ref [45-50,52,53]. 






expected is more soluble than 56 in organic solvents (Scheme 
10). Nevertheless, in contrast with the first expectations, this 
complex showed a substantial enhancement of the 
antiproliferative activity with respect to the starting complex 56, 
constituting the first component of the so-called 2nd generation of 
this family of complexes containing dmoPTA.[50] The obtained 
GI50 values, for the same panel of tumour cancer cells, which 
are given in Table 1, show that this compound displays a bigger 
antiproliferative activity than those for cisplatin and RAPTA 
complexes (in the range 0.17−0.29 μM). Noteworthy differences 
between the antiproliferative activity of 63 and cisplatin were 
observed for T-47D (ca. 70:1) and WiDr (>100:1) cells, which 
are the more cisplatin-resistant cellular lines. The cell cycle 
phase distribution of this complexes studied by flow cytometry[51] 
showed to be clearly different to that for cisplatin (Figure 4). Cell 
cycle experiments discarded DNA as the main biological target 
of these complexes. The charge density calculation of the 
complex 63 with density functional theory (DFT) showed that the 
electronic distributions in the monometallic Ru complexes of the 
first and second complex generations are similar and could not 
justify the large antiproliferative activity differences found 
between them. The calculation results suggest that there are not 
probable interactions between the complexes and the negatively 
charged cell membrane.  
The experimental results indicate that the antiproliferative 
activity of 56 is not dependent on the substitution of the Cl by 
another ligand, such as a DNA or other bio-molecules. This 
conclusion opens the door to obtain a large library of complexes 
probably with larger and tuned antiproliferative activity by 
substitution of the Cl in 55 by other ligands with different 
electronic and steric properties and solubility. It is evident that 
the next step to be accomplished was the synthesis of the 
biheterometallic complexes by coordination of a metal unit to 
dmoPTA-NCH3, expecting that these bimetallic complexes 
showed higher antirproliferative activity than the starting 
monometallic Ru complex 63. All the presuntions were 
confirmed by the synthesis of the new bimetallic Ru-Co complex 
[RuCp(PPh3)2-μ-dmoPTA-1κP:2κ2N,N’-CoCl2](OTf)·0.25H2O (65) 
that was obtained by reaction of 63 with potassium terbutoxide 
(T-butOK), providing the deprotonate complex 64, and further 
reaction with CoCl2·6H2O in MeOH (Scheme 10).[52] The 
antiproliferative activity of this complex was found to be much 
better than that for starting complex. Similarly to that observed 
for starting complex 63, the Ru-Co complex 65 produces the 
accumulation of cells in the G1 phase of the cell cycle (Table 1), 
which indicates that both complexes show a comparable 
mechanism of action against the studied cell lines. 
The Ru-Co complex 65 in DMSO-d6 at room temperature 
releases in short time (10 min) the {CoCl2} unit and the 
deprotonated complex {RuCp(PPh3)2(dmoPTA)}+. Quick addition 
of water (or cell culture) avoids the fast release of the {CoCl2} 
unit. In this mixture of solvents, the complete release of this 
moiety is obtained in 2 hours at 40 °C. The elimination of PPh3 
was also observed, but after more than one day only a 5% of the 
Scheme 10. Synthesis of complexes 63-66. 
Figure 5. Representation of the crystal structures of 62, 64 and 65. Adapted from ref [50, 52,53] 






phosphine was eliminated. Interestingly, it was also reported that, 
in a lipophilic environment as the solvent CDCl3, the complex 
releases PPh3 for first and then the {CoCl2} moiety. 
The obtained experimental results suggested that inside 
the cell the {CoCl2} moiety, which is inactive outside, act as an 
antiproliferative agent and/or synergize the activity of the other 
released product such as the {RuCp(PPh3)2(dmoPTA)}+ complex 
and the ligand PPh3. The authors propose that the complex 
could work as a “Trojan horse” to introduce all these compounds 
into the cell. As a conclusion, it is evident that the combination of 
the metal units containing Ru and Co in the complex leads to a 
significant enhancement of the antiproliferative activity of both 
metal units. When Cl is in the medium, cationic complex 
{RuCpCl(PPh3)(dmoPTA-1kP)}+ was also observed. 
Protonation/deprotonation of this complex showed to have a 
non-significant influence on its antiproliferative activity, as it was 
similar than that for deprotonated complex 64 (Table 1). 
 
 
The last published example of this second generation of 
bimetallic compounds containing dmoPTA is the Ru-Zn complex 
RuCp(PPh3)2-μ-dmoPTA-1kP:2k2N,N’-ZnCl2](CF3SO3) (66).[56] 
This compound was initially synthetized by a procedure similar 
to that used for previously described bimetallic complexes, but it 
was revelled to be not good enough as is very sensitive to 
reaction conditions.[53] A new synthetic procedure was designed 
from the complex [RuCp(PPh3)2(1kP-dmoPTA-)](CF3SO3) (64), 
which was synthetized by reaction of starting complex 63 with 
1.1 equivalent of t-ButOK in THF (Scheme 10). The 
deprotonated complex is stable in solid state for months and 
soluble in organic solvents such as CHCl3. Reaction of this 
complex with ZnCl2 in EtOH provide the Ru-Zn complex 66 by a 
robust method (Scheme 10). 
The new Ru-Zn complex (66) displays a better activity (1.2-2.5 
times) than the sibling Ru-Co and much better (26-426 times) 
than cisplatin. Remarkably, complex 66 is alo 3-8 times more 
active against the tumour cell lines than against the tested non-
tumour cell line (non-tumour human cell line BJ-hTert) while 
starting monometallic deprotonate complex 64 shows similar 
toxicity against tumour and non-tumour cells. Complex 66 is 
significantly more stable than 65 complex. Therefore, stability 
studies suggest that the observed higher antiproliferative activity 
of 66 should be consequence of its bimetallic nature and the 
adequate combination of metals. 
The structure of the published complexes containing the 
ligand dmoPTA are similar (Figure 3 and 5). The ligands are 
disposed around the Ru with a piano-stool disposition 
constituted by a η5-Cp, a Cl (or PPh3), a PPh3 and a dmoPTA 
bonded by the P atom. The bimetallic complexes substituted the 
H bonded to the dmoPTA-NCH3 atoms by a metal unit. Selected 
bond lengths and angles for these complexes are included in 
Table 2. The 31P NMR chemical shift for the dmoPTA ligand is 
also includes in Table 2. The chemical shift shows if the 
complexes are monometallic or bimetallic and the magnetic 
nature of the metal bonded to the dmoPTA-NCH3 atoms. 
Complexes containing dmoPTA have showed a very high 
antiproliferative activity, being the Ru-Zn complex 66 the most 
active of the family synthesized until now. This complex is also 
one of the most antiproliferative complexes among those 
published, and also displays a significant selectivity between 
tumour and non-tumour cells. Considering that the number of 
complexes containing the ligand dmoPTA is still scarce and 
there are a large amount of possible combinations of metal and 
ancillary ligands, new compounds with improve properties are 
expected to be obtained in short future. 
Conclusions  
Despite the large time from the discovery of cisplatin and the 
intense research devoted to find new compounds with improved 
antiproliferative properties, and the large number of interesting 
complexes synthesized and studied; there are not any valuable 
 Bond Lengths (Å) 
 55 56 57 58 60 61 62 64 65 
Ru-Cp 2.221(9)b 2.183(12)b 1.839(1) 1.855(1) 1.853(2) 1.845(5) 2.239(5)b 1.893 1.894 







Ru-P(dmoPTA) 2.277(3) 2.436(3) 2.288(2) 2.2943(19) 2.279(7) 2.276(2) 2.3207(11) 2.319(7) 2.3148(10) 
Ru-Cl 2.447(2) 2.436(3) 2.4410(19) 2.448(2) 2.445(7) 2.447(2)    
 Angles (º) 
N-M-N  81.8(3) 83.2(2) 80.9(2) 91.40(9) 91.10(18)  91.92(11) 90.16(15) 
Table 2. Selected bond distances and angles for complexes 56-66. Adapted from ref [45-50,52,53]. 






alternative with metals different to platinum that finally can be 
used as medicine drugs for the treatment of cancer. New metal 
complexes useful in medicine have to be still synthesized, which 
have to display also selective and improve antiproliferative 
properties, with lower side effects, with an easier and less 
intrusive administration. Additionally, these new complexes have 
to be easily available to all population and therefore they should 
be obtained by easy and cheap procedures. Complexes 
containing PTA and its derivatives, particularly the dmoPTA, are 
among the most promising new compounds that could give 
answers to these requirements. 
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